Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DAWN

Day One Biopharmaceuticals Inc

Mar 30 • 09:52AM ET

21.42

+0.01 0.02 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX NBIX BPMC SRPT EXEL FATE IGMS KURA BHVN PBYI

| Held by: IWM VTI XBI IWN IBB VB VXF SCHA DFAS VBR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.04	Insider Own	26.57%	Shs Outstand	102.98M	Perf Week	0.26%
Market Cap	2.21B	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-0.23%	Shs Float	75.85M	Perf Month	102.03%
Enterprise Value	1.77B	PEG	-	EPS next Q	-0.28	Inst Own	74.07%	Short Float	10.67%	Perf Quarter	126.61%
Income	-107.32M	P/S	13.98	EPS this Y	25.02%	Inst Trans	-6.73%	Short Ratio	1.85	Perf Half Y	216.32%
Sales	158.18M	P/B	5.00	EPS next Y	76.31%	ROA	-19.68%	Short Interest	8.09M	Perf YTD	129.77%
Book/sh	4.28	P/C	5.01	EPS next 5Y	-	ROE	-22.74%	52W High	21.46 -0.21%	Perf Year	165.37%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	21.77% -9.72%	ROIC	-24.18%	52W Low	5.64 280.04%	Perf 3Y	67.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.12%	Volatility	0.23% 2.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	11.21	EPS Y/Y TTM	-0.47%	Oper. Margin	-80.76%	ATR (14)	0.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.91	Sales Y/Y TTM	20.60%	Profit Margin	-67.85%	RSI (14)	81.52	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.02	EPS Q/Q	68.21%	SMA20	7.49%	Beta	-1.90	Target Price	21.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	83.92%	SMA50	44.48%	Rel Volume	0.26	Prev Close	21.41
Employees	178	LT Debt/Eq	0.01	Earnings	Feb 24 AMC	SMA200	126.47%	Avg Volume	4.37M	Price	21.42
IPO	May 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-41.03% 7.75%	Trades		Volume	115,771	Change	0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-26	Downgrade	H.C. Wainwright	Buy → Neutral	$21.50
Jan-13-26	Resumed	TD Cowen	Buy	$34
Aug-19-25	Initiated	Piper Sandler	Overweight	$25
Oct-09-24	Reiterated	Needham	Buy	$32 → $33
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy	$11 → $24
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

Show Previous Ratings

Mar-27-26 05:49AM	Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-12-26 01:52PM	Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-11-26 09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
Mar-10-26 09:34AM	Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls (The Fly)
08:06AM	Loading…
08:06AM	Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's,Qualcomm, Rivian, Strategy and More (24/7 Wall St.)
04:00AM	Serviers $2.5B cancer bet underlines a quick oncology growth strategy (Pharma Voice)
Mar-09-26 01:25PM	Are DAWN and TALK Obtaining Fair Deals for their Shareholders? (PR Newswire)
09:10AM	DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier (Zacks)
06:34AM	Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen (MarketBeat)
Mar-07-26 08:31PM	Day One (DAWN) Soars 100% on $2.5-Billion Merger (Insider Monkey)
01:41AM	Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger (Insider Monkey)
Mar-06-26 04:09PM	Day One Skyrockets On Servier's $2.5 Billion Buyout. Could A 'White Knight' Emerge? (Investor's Business Daily)
12:08PM	This Biopharma Company Is Being Bought for $2.5 Billion. Its Stock Is Up 66%. (Barrons.com)
10:29AM	Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio (PR Newswire)
10:04AM	Loading…
10:04AM	Day One Shares Surge After $2.5B Servier Deal (Benzinga)
09:18AM	Day One Biopharmaceuticals Skyrockets On Servier's $2.5 Billion Buyout (Investor's Business Daily)
09:14AM	Servier to Buy Day One for $2.5 Billion, Expanding Oncology Portfolio (The Wall Street Journal)
07:24AM	Servier to build cancer drug pipeline with $2.5B purchase of Day One (BioPharma Dive)
Feb-25-26 12:03AM	Day One Biopharmaceuticals Inc (DAWN) Q4 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Feb-24-26 11:11PM	Day One Biopharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:04PM	Day One Biopharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
07:30PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:00PM	Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance (GlobeNewswire)
Feb-23-26 07:24AM	Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q4 2025 Result (GuruFocus.com)
Feb-18-26 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-17-26 10:00AM	Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-13-26 09:40AM	Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-10-26 08:30AM	Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 (GlobeNewswire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
12:27PM	Loading…
Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Jan-27-26 10:00AM	Best Momentum Stocks to Buy for January 27th (Zacks)
04:16AM	New Strong Buy Stocks for January 27th (Zacks)
Jan-23-26 07:32AM	Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Jan-21-26 04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
Jan-15-26 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet (Zacks)
Jan-13-26 09:21AM	Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? (Zacks)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-11-26 05:00PM	Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance (GlobeNewswire)
Jan-08-26 05:00AM	Day One concludes Mersana Therapeutics acquisition (Pharmaceutical Technology)
Jan-06-26 09:02AM	Day One Completes Acquisition of Mersana Therapeutics (GlobeNewswire)
Dec-16-25 08:30AM	Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) (Insider Monkey)
Dec-11-25 10:31AM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
Nov-24-25 08:00AM	Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-18-25 08:30AM	Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade (Zacks)
Nov-13-25 04:31PM	Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily)
09:07AM	Mersana Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily)
06:59AM	Day One snaps up ADC maker Mersana in backloaded buyout deal (BioPharma Dive)
06:00AM	Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases (GlobeNewswire)
Nov-10-25 07:00AM	Day One Announces New OJEMDA (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-05-25 12:06AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Day One Reports Third Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Nov-03-25 07:53AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 09:55AM	Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Oct-21-25 08:30AM	Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 (GlobeNewswire)
Oct-14-25 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet (Zacks)
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Sep-16-25 08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-08-25 12:30AM	Piper Sandler Starts Coverage on Day One (DAWN) with Overweight Rating (Insider Monkey)
Aug-19-25 12:10AM	H.C. Wainwright Reiterates 'Buy' Rating on Day One Biopharmaceuticals, Inc. (DAWN) (Insider Monkey)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-06-25 03:31AM	Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Aug-05-25 04:00PM	Day One Reports Second Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Aug-04-25 09:54AM	Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade (Zacks)
Jul-22-25 08:30AM	Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development (GlobeNewswire)
May-13-25 10:47AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-09-25 07:54AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 11:09AM	Q1 2025 Day One Biopharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:21AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Day One Reports First Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
May-05-25 10:00AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
May-03-25 02:13AM	Q1 2025 American International Group Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 08:30AM	Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 (GlobeNewswire)
Apr-10-25 11:51PM	Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity (Seeking Alpha)
Apr-09-25 09:44AM	Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple (Insider Monkey)
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-20-25 01:00AM	EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan (WWD)
Mar-05-25 09:00AM	Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory (Insider Monkey)
Feb-25-25 05:55PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress (GlobeNewswire)
01:36AM	Day One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-13-25 09:55AM	Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? (Zacks)
Feb-11-25 08:30AM	Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 (GlobeNewswire)
Jan-28-25 08:56AM	Trump pledged to bring down food prices on Day One. Instead, eggs are getting more expensive (CNN Business)
05:30AM	Trump said hed bring prices down on Day One. That hasnt happened (CNN Business)
Jan-23-25 01:02AM	Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? (Insider Monkey)
Jan-22-25 08:44AM	New Tariffs Didnt Come on Trumps Day One. A Trade War May Not Be in the Wings. (Barrons.com)
Jan-20-25 03:31PM	President Trump outlines a frenzy of Day One executive orders and actions: Heres a list of what to expect (FastCompany)
Jan-13-25 08:00AM	Day One Reports Preliminary 2024 OJEMDA Net Product Revenue and Highlights 2025 Corporate Priorities (GlobeNewswire)
Dec-24-24 04:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-22-24 03:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Merendino Lauren	Chief Commercial Officer	Feb 17 '26	Sale	11.60	5,814	67,448	60,157	Feb 18 05:18 PM
Dubow Adam	Gen Counsel & Secretary	Feb 17 '26	Sale	11.60	6,395	74,188	72,694	Feb 18 05:17 PM
York Charles N II	COO and CFO	Feb 17 '26	Sale	11.60	6,065	70,359	312,025	Feb 18 05:16 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 17 '26	Sale	11.60	15,459	179,338	204,603	Feb 18 05:14 PM
VASCONCELLES MICHAEL	Head of Research and Dev.	Feb 17 '26	Sale	11.60	2,728	31,647	4,397	Feb 18 05:13 PM
JEREMY BENDER	Officer	Feb 17 '26	Proposed Sale	11.60	15,459	179,338		Feb 17 06:21 PM
CHARLES YORK	Officer	Feb 17 '26	Proposed Sale	11.60	6,065	70,359		Feb 17 06:18 PM
LAUREN MERENDINO	Officer	Feb 17 '26	Proposed Sale	11.60	5,814	67,448		Feb 17 06:13 PM
ADAM DUBOW	Officer	Feb 17 '26	Proposed Sale	11.60	6,395	74,188		Feb 17 06:08 PM
Dubow Adam	Gen Counsel & Secretary	Nov 17 '25	Sale	8.91	4,319	38,503	62,626	Nov 18 07:04 PM
York Charles N II	COO and CFO	Nov 17 '25	Sale	8.91	4,062	36,212	294,715	Nov 18 07:02 PM
Merendino Lauren	Chief Commercial Officer	Nov 17 '25	Sale	8.91	3,726	33,216	50,809	Nov 18 07:00 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Nov 17 '25	Sale	8.91	15,894	141,690	177,165	Nov 18 06:59 PM
CHARLES YORK	Officer	Nov 17 '25	Proposed Sale	8.91	4,062	36,211		Nov 17 04:12 PM
LAUREN MERENDINO	Officer	Nov 17 '25	Proposed Sale	8.91	3,726	33,216		Nov 17 04:12 PM
ADAM DUBOW	Officer	Nov 17 '25	Proposed Sale	8.91	4,319	38,502		Nov 17 04:11 PM
JEREMY BENDER	Officer	Nov 17 '25	Proposed Sale	8.91	15,894	141,689		Nov 17 04:09 PM
York Charles N II	COO and CFO	Aug 18 '25	Sale	6.77	4,106	27,786	278,000	Aug 19 07:40 PM
Dubow Adam	Gen Counsel & Secretary	Aug 18 '25	Sale	6.77	4,365	29,538	54,858	Aug 19 07:38 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Aug 18 '25	Sale	6.77	16,058	108,666	161,365	Aug 19 07:37 PM
Merendino Lauren	Chief Commercial Officer	Aug 18 '25	Sale	6.77	3,766	25,485	41,931	Aug 19 07:36 PM
JEREMY BENDER	Officer	Aug 18 '25	Proposed Sale	6.77	16,058	108,666		Aug 18 05:33 PM
Merendino Lauren	Chief Commercial Officer	May 16 '25	Sale	6.26	3,927	24,575	35,161	May 19 05:54 PM
Dubow Adam	GENERAL COUNSEL	May 16 '25	Sale	6.26	4,552	28,486	47,136	May 19 05:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '25	Sale	6.26	4,282	26,796	265,231	May 19 05:45 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '25	Sale	6.26	13,964	87,385	145,737	May 19 05:44 PM
CHARLES YORK	Officer	May 16 '25	Proposed Sale	6.26	4,282	26,796		May 16 04:09 PM
LAUREN MERENDINO	Officer	May 16 '25	Proposed Sale	6.26	3,927	24,575		May 16 04:09 PM
ADAM DUBOW	Officer	May 16 '25	Proposed Sale	6.26	4,552	28,486		May 16 04:08 PM
JEREMY BENDER	Officer	May 16 '25	Proposed Sale	6.26	13,964	87,385		May 16 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DAWN

Day One Biopharmaceuticals Inc

Upgrade your Finviz experience